Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Safety of Tapentadol (CG5503) in the Treatment of Acute Pain After Abdominal Hysterectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Female between 18 and 80 years of age;~* Scheduled to undergo an abdominal hysterectomy with or without bilateral salpingo-oophorectomy due to uterine leiomyomas, or dysfunctional uterine bleeding or endometrial hyperplasia;~* Anesthesiological and surgical procedures performed according to protocol;~* Moderate or severe baseline pain following hysterectomy on a Verbal Rating Scale (VRS) within 6 hours following the last possible application of morphine subcutaneous;~* Pain following hysterectomy of at least 4 on an 11-point Numeric Rating Scale (NRS) within 6 hours following the last possible application of morphine subcutaneous;~* American Society of Anesthesiologists (ASA) classification I-III.~Exclusion Criteria:~* Vaginal hysterectomy;~* Ongoing or known history of painful endometriosis;~* Known or suspected chronic pelvic pain syndrome;~* Previous abdominal or pelvic open surgery;~* History of seizure disorder or epilepsy;~* History of alcohol or drug abuse;~* Evidence of active infections that may spread to other areas of the body;~* severely impaired renal function, moderately or severely impaired hepatic function,~* Allergy or hypersensitivity to oxycodone, morphine, fentanyl hydromorphone, heparin, or any compound planned to be used during the anesthesia;~* Serious complication during surgery and up to randomization;~* Pre-operative use within 12hours prior to surgery or peri-operative use of non-steroidal anti-inflammatory drugs (NSAIDs);~* Treated regularly with opioid analgesic or non-steroidal anti-inflammatory drugs (NSAIDs) within 30 days prior to screening;

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Morphine (Type: ACTIVE_COMPARATOR): None
- Tapentadol 50 mg immediate release (Type: EXPERIMENTAL): None
- Tapentadol 75 mg immediate release (Type: EXPERIMENTAL): None
- Tapentadol 100 mg immediate release (Type: EXPERIMENTAL): None
- Matched placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).